Aprilbio exhibited a strong stock price trend on the 10th, drawing keen interest from investors. During the day's trading, buying pressure concentrated to the point of triggering the Volatility Interruption (VI), drawing market attention. According to the Korea Exchange, a static VI was triggered and subsequently lifted during the morning session, recording high volatility.

'Bio stocks' differentiation draws attention amid escalating Middle East tensions Recent global financial markets are on high alert over escalating military tensions in the Middle East. Following the U.S. military helicopter crash, observations have emerged that the United States conducted airstrikes targeting pro-Iranian forces in the Middle East, leading to increased volatility in international oil prices and stock markets. Iran has also indicated the possibility of a hardline response, further heightening investors' vigilance. However, in the domestic stock market, a trend of stock differentiation centered on growth industries continues despite geopolitical anxieties. In particular, the bio industry sees active trading focused on individual stocks, as factors such as new drug development, technology transfers, and research and development (R&D) results have a more direct impact on corporate value than the international situation. Recently, across the overall bio industry, the preference for growth stocks has partially recovered alongside expectations for interest rate stability, expanding interest in companies equipped with technological prowess and competitive pipelines.

Aprilbio's growth story utilizing platform technology Aprilbio, an antibody-based new drug development company, possesses a platform technology for long-acting protein drugs. The market is focusing on the development of candidate substances using its proprietary platform and the potential for collaborations with global pharmaceutical companies, with R&D achievements being evaluated as a key variable for future corporate value. Experts analyze that while concerns over a conflict between the United States and Iran could increase short-term market volatility, the long-term value of bio companies is ultimately determined by their R&D performance and commercialization. Therefore, they advise investors to look beyond the international situation and also examine clinical progress, the possibility of technology exports, and potential improvements in financial performance. Meanwhile, the market is closely watching variables such as the possibility of additional U.S. airstrikes, the level of Iran's response, and shifts in global bio investment sentiment. Attention is now focused on whether Aprilbio's individual growth story can be highlighted within this market environment.

[This article was written for the purpose of providing investment information, and the investment decision and responsibility lie with the investor. AI was partially used in the writing process of this article.]